Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder

Simple item page
dc.contributor.authorLekili M.
dc.contributor.authorŞener E.
dc.contributor.authorDemir M.A.
dc.contributor.authorTemeltaş G.
dc.contributor.authorMüezzinoǧlu T.
dc.contributor.authorBüyüksu C.
dc.date.accessioned2024-07-22T08:24:17Z
dc.date.available2024-07-22T08:24:17Z
dc.date.issued2004
dc.description.abstractSeveral urinary markers for transitional cell carcinoma have been investigated, including urine cytology, bladder tumor antigen, autocrine motility factor receptor and fibrin degradation products. Unfortunately, they have poor overall sensitivity. The United States Food and Drug Administration have recently approved nuclear matrix protein (NMP 22) for the detection of occult or rapidly recurring disease after transurethral resection of bladder tumor. The objective of the current study was to assess the sensitivity of NMP 22 for the detection of bladder carcinoma, as well as to correlate the NMP 22 values with multiplicity of tumor, tumor size, configuration, stage and grade respectively. A total of 78 patients (38 with bladder cancer) provided a urine sample which was divided into appropriate aliquots for each of urine cytology and NMP 22. Comparative results demonstrate a clear superiority of NMP 22 in bladder cancer detection (52.6% vs 31.6% sensitivity), while specificity was in favor of urine cytology (100% vs 82.5%). For superficial tumors, sensitivity was 78.5% for NMP 22 and 41.6% for cytology and for invasive cancers, sensitivity was 90% for NMP 22 and 60% for cytology. Urinary NMP 22 levels were significantly correlated with tumor grade and were significantly higher in large tumors than small tumors. NMP 22 test results showed sufficient sensitivity in comparison with urine cytology for the detection of transitional cell carcinoma. However, we do not think that it is a useful tool as a substitute for endoscopic examination for the detection and surveillance in bladder cancer.
dc.identifier.DOI-ID10.1007/s00240-003-0394-2
dc.identifier.issn03005623
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19912
dc.language.isoEnglish
dc.subjectCarcinoma, Transitional Cell
dc.subjectHumans
dc.subjectNeoplasm Staging
dc.subjectNuclear Proteins
dc.subjectPredictive Value of Tests
dc.subjectProspective Studies
dc.subjectReproducibility of Results
dc.subjectSensitivity and Specificity
dc.subjectTumor Burden
dc.subjectTumor Markers, Biological
dc.subjectTurkey
dc.subjectUrinary Bladder Neoplasms
dc.subjectautocrine motility factor receptor
dc.subjectnuclear matrix protein
dc.subjectnuclear matrix protein 22
dc.subjecttumor antigen
dc.subjectunclassified drug
dc.subjectarticle
dc.subjectbladder carcinoma
dc.subjectcancer diagnosis
dc.subjectcancer invasion
dc.subjectcontrolled study
dc.subjectdiagnostic value
dc.subjectfibrinolysis
dc.subjectfood and drug administration
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectpriority journal
dc.subjectprotein analysis
dc.subjectprotein urine level
dc.subjectsensitivity analysis
dc.subjecttransitional cell carcinoma
dc.subjecttransurethral resection
dc.subjecttumor volume
dc.subjecturinalysis
dc.subjecturine cytology
dc.subjecturodynamics
dc.titleComparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder
dc.typeArticle

Files

Collections

Scopus Koleksiyonu